Pfizer Inc. has announced price hikes for approximately 80 medications, including a 15% increase for its COVID-19 vaccine, as the company grapples with a 60% stock decline since its 2021 highs. This move comes in a challenging environment marked by lower COVID-related sales, patent expirations, and setbacks in its drug pipeline, prompting Pfizer to acquire the smaller company Metsera for $7 billion to enhance its offerings. Despite these difficulties, analysts maintain a cautiously optimistic outlook, reaffirming a $30 target price, while concerns about the sustainability of its dividend payout linger.
“Citing the company’s cautious 2026 outlook, BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on December 17.”
“Pfizer · announced · list price hikes · on around 80 different drugs”
“Pfizer · is raising · its COVID vaccine price · 15%”
“Pfizer · stock price change · during the coronavirus pandemic · soared”
“Pfizer · stock price change · current status · plunged”
“Pfizer · stock decline percentage · from 2021 highs · 60%”
“Pfizer · relationship with patent expirations · current situation · facing significant headwinds”
“Pfizer · pipeline setback · GLP-1 weight loss candidate · failed to meet expectations”
“Pfizer · activity after GLP-1 drug failure · acquired a smaller drug company · to obtain a promising GLP-1 drug candidate”
“Pfizer · is seeking increases for · about 80 drugs”
“Pfizer · includes the cancer therapy · Ibrance”
“Pfizer · includes the migraine treatment · Nurtec”